Ivanka Krznaric
Overview
Explore the profile of Ivanka Krznaric including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
896
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Post G, Shalev N, Baumgarten A, Shimakawa Y, Lemoine M, Krznaric I, et al.
Eur J Gastroenterol Hepatol
. 2019 Apr;
31(6):723-728.
PMID: 30964812
Background And Aims: The prevalence of chronic hepatitis B virus (HBV) infection in Europe is poorly defined. Data on the proportion of patients eligible for therapy are lacking but are...
12.
Spinner C, Hanhoff N, Krznaric I, Knecht G, Kuemmerle T, Ruesenberg R, et al.
Infection
. 2018 Feb;
46(3):405-408.
PMID: 29478091
Prupose: To examine current risk behavior, awareness, experience, and attitudes towards pre-exposure-prophylaxis (PrEP), and to estimate a potential impact on the prevention of HIV transmission among HIV-negative MSM in Germany....
13.
Spinner C, Boesecke C, Jordan C, Wyen C, Kummerle T, Knecht G, et al.
Infection
. 2018 Feb;
46(3):341-347.
PMID: 29460228
Purpose: Sexually transmitted infections (STIs) occur frequently in risk populations. Hereby, the role of screening-programmes remains controversial. Our study aimed to determine the prevalence of STI infections in HIV-positive men-who-have-sex-with-men...
14.
Boretzki J, Wolf E, Wiese C, Noe S, Balogh A, Meurer A, et al.
Patient Prefer Adherence
. 2017 Nov;
11:1897-1906.
PMID: 29184394
Background: Reasons for and frequency of nonadherence to antiretroviral therapy (ART) may have changed due to pharmacological improvements. In addition, the importance of known non-pharmacologic reasons for nonadherence is unclear....
15.
Spinner C, Kummerle T, Krznaric I, Degen O, Schwerdtfeger C, Zink A, et al.
J Antimicrob Chemother
. 2017 Sep;
72(9):2679-2681.
PMID: 28859438
No abstract available.
16.
Rodger A, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, et al.
JAMA
. 2016 Jul;
316(2):171-81.
PMID: 27404185
Importance: A key factor in assessing the effectiveness and cost-effectiveness of antiretroviral therapy (ART) as a prevention strategy is the absolute risk of HIV transmission through condomless sex with suppressed...
17.
Hoffmann C, Schommers P, Wolf E, Muller M, Schultze A, Krznaric I, et al.
AIDS
. 2015 Nov;
30(5):753-60.
PMID: 26605513
Objective: The risk of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) is increased in HIV-infected individuals. We studied the kinetics of lymphocyte subsets in patients who subsequently developed HL or...
18.
Ehret R, Walter H, Ingiliz P, Baumgarten A, Obermeier M, Krznaric I
J Int AIDS Soc
. 2014 Nov;
17(4 Suppl 3):19644.
PMID: 25394148
Introduction: Due to drug-drug interactions of HIV- and HCV-specific antivirals when initiating an HCV-therapy, the antiretroviral therapy (ART) often has to be changed. The spectrum of applicable antiretrovirals is small,...
19.
Ingiliz P, Steininger K, Schuetze M, Dupke S, Carganico A, Krznaric I, et al.
J Int AIDS Soc
. 2014 Nov;
17(4 Suppl 3):19638.
PMID: 25394142
Introduction: Acute hepatitis C virus (HCV) infection has emerged as a major cause of morbidity in the HIV-infected population. Most guidelines recommend early treatment with pegylated interferon and ribavirin due...
20.
Baran R, Mulcahy F, Krznaric I, Monforte A, Samarina A, Xi H, et al.
J Int AIDS Soc
. 2014 Nov;
17(4 Suppl 3):19616.
PMID: 25394120
Introduction: Global HIV-1 prevalence is 35.3 million [1]; women comprise >50% of those infected. The majority of women may lack regular care and only one-fourth are virologically suppressed [2]. ELLA...